Press news Biocartis Group NV: Biocartis Announces Market Release
of SeptiCyte® RAPID test on Idylla™
PRESS RELEASE: 6 October 2020, 07:00
CEST
Biocartis Announces Market Release of
SeptiCyte® RAPID test on Idylla™
Mechelen, Belgium, 6 October
2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’),
an innovative molecular diagnostics company (Euronext Brussels:
BCART), today announces the market release of SeptiCyte® RAPID on
Idylla™ as a CE-marked IVD test. SeptiCyte® RAPID is a
host-response test1 that distinguishes sepsis from non-infectious
systemic inflammation in patients suspected of sepsis and provides
actionable results in about one hour. The test was developed by
Biocartis’ partner Immunexpress Pty Ltd (‘Immunexpress’), a
Seattle-based (US) molecular diagnostics company, and is now being
released as part of Biocartis’ exclusive commercialization2 of
SeptiCyte® RAPID on Idylla™ in Europe.
Sepsis is the body’s life-threatening response
to infection, which can lead to tissue damage, organ failure, and
death3. A recent scientific publication by The Lancet estimated
that in 2017 there were 48.9 million cases and 11 million
sepsis-related deaths worldwide, which accounted for almost 20% of
all global deaths4. Early and rapid diagnosis of sepsis is
furthermore essential to avoid unnecessary hospital costs or
overuse of antibiotics, which leads to greater antibiotic
resistance among vulnerable patient populations.
Current diagnostic tests to aid in the diagnosis
of sepsis are often unreliable and slow. At the virtual e-ISICEM
symposium5 held between 15-18 September 2020, Immunexpress
presented clinical validation data6 which demonstrated comparable
and reproducible results between Immunexpress’ existing US
FDA-cleared test, SeptiCyte® LAB, and SeptiCyte® RAPID on Idylla™.
These data are the first validation of a rapid, fully-integrated,
reproducible, immune response-based sepsis diagnostic test6.
Herman Verrelst, Chief Executive Officer
of Biocartis, reacted: “Together with our partner
Immunexpress, the SeptiCyte® and Idylla™ technologies joined forces
in a single one-step, sample-to-result test that, thanks to the
Idylla™ platform, can now be rolled out globally. As the exclusive
distributor of SeptiCyte® RAPID in Europe, we are very pleased to
offer this test to our existing and new customer base within our
well-established European laboratory and hospital network. I
believe we can make a real difference with this test that now
allows7 to detect the likelihood of sepsis early on and provides
actionable results to clinicians in approximately one hour for
critically-ill patients suspected of sepsis, where every second
counts."
SeptiCyte® RAPID on Idylla™ as CE-marked IVD test is now
available8 for ordering. More info can be found on the Biocartis
website.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail
rdegrave@biocartis.comtel
+32 15 631 729 mobile +32 471 53 60
64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer. More
information: www.biocartis.com. Follow us on Twitter:
@Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
This press release is not for distribution, directly or indirectly,
in any jurisdiction where to do so would be unlawful. Any persons
reading this press release should inform themselves of and observe
any such restrictions. Biocartis takes no responsibility for any
violation of any such restrictions by any person. Please refer to
the product labeling for applicable intended uses for each
individual Biocartis product. This press release does not
constitute an offer or invitation for the sale or purchase of
securities in any jurisdiction. No securities of Biocartis may be
offered or sold in the United States of America absent registration
with the United States Securities and Exchange Commission or an
exemption from registration under the U.S. Securities Act of 1933,
as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
1 By testing whole blood directly, the assay is able to detect
the response of the patient’s immune system to an infection
earlier, faster and more accurately than finding the pathogen
2 As announced on 26 March 2020
3 Source: https://www.sepsis.org/, last consulted on 24
September 2020
4 Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan
DR, et al. Global, regional, and national sepsis incidence and
mortality, 1990-2017: analysis for the Global Burden of Disease
Study. Lancet (London, England). 2020;395(10219):200-11
5 International Symposium on Intensive Care and Emergency
Medicine
6 Source: Immunexpress website and on
https://www.prnewswire.com/news-releases/immunexpress-presents-data-on-clinical-validation-of-septicyte-rapid-for-diagnosing-sepsis-at-e-isicem-301130702.html,
last consulted on 24 September 2020
7 Used in conjunction with clinical assessments, vital signs and
laboratory findings
8 Available to select countries within the EU and European
region. Check availability with your local Biocartis
representative
Grafico Azioni Biocartis Group NV (EU:BCART)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocartis Group NV (EU:BCART)
Storico
Da Apr 2023 a Apr 2024